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Objective. Intracellular localization of translationally controlled tumour protein (TCTP) was investigated in cancer cells. Methods.
The expression and localization of TCTP were detected at 12h, 24h, 48h, 60h time points in culture of human hepatocarcinoma
cell line HepG2, human cervical carcinoma cell line HeLa, and human normal liver cell line HL-7702 by immunoﬂuorescence.
Results. TCTP was expressed in both normal and tumor cells, and its localization changes at diﬀerent time points. TCTP was
mainly expressed in cytoplasm from 24h to 48h then expressed in both nucleus and cytoplasm at 60h in HL-7702 cells. While
in HepG2 cells, TCTP ﬁrst localized at cell membrane within 24h then at both nucleus and cytoplasm from 48h to 60h; TCTP
localized at both nucleus and cytoplasm from 12h to 60h in Hela cells. Conclusion. The translocation of intracellular expression
of TCTP in normal and tumor cells at diﬀerent time points may pave a path to the studying of TCTP role in tumor growth.
1.Background
The translationally controlled tumor protein (TCTP), a
highly conversed protein [1, 2], also called the histamine
releasing factor (HRF) [3], has been suggested as a tumor-
associated antigen and widely expressed in mammals as well
as in a wide range of other organisms of both animal and
plant kingdom [4]. Its mRNA and protein expression levels
tend to be higher in the colorectal cancers (CRCs) [5]a n d
hepatocellular carcinoma [6], compared to the correspond-
ingnormaltissues.TCTPwasfoundtobethemoststrikingly
downregulated in tumor reversion [7]. Moreover, the level of
TCTP in the revertants from three other major solid cancers,
colon, lung, and melanoma cell lines, has the same results
[5, 8, 9]. In addition, transfection with antisence of TCTP
attenuated malignancy of v-src-transformed NIH3T3 cells.
Recently, TCTP has attracted the attention of an increasing
number of researchers interested in various biologically and
medically relevant processes. This is largely due to the fact
that TCTP levels are highly upregulated in response to a
wide range of extracellular stimuli [10, 11]. A series of recent
reports highlighted the importance of TCTP for cell cycle
progression and malignant transformation [12, 13]. TCTP
was also shown to display an extracellular function as a
histamine release factor and to have antiapoptotic activity
[14].
The intracellular localization of TCTP remains contro-
versy. It was shown to localize in cytoplasm by Arcuri et al.
[15] and nucleus by Li et al. [14], respectively. TCTP
can be secreted and tumor-suppressor-activated pathway-6
(TSAP6) facilitates the secretion of TCTP via a nonclassical
pathway through exosomes which highlights the association
of TCTP and TSAP6 in cytoplasm [16]. The purpose of our
study was to determine the localization of TCTP expression
in two human cancer cell lines and one normal cell line. We
applied cell immunoﬂuorescence and detected the protein
expression of TCTP at diﬀerent time points in these three
cell lines. We found that TCTP localized in both cytoplasm
andnucleusanditstranslocationvariedbetweennormaland
tumor cell lines at diﬀerent time points.
2.MaterialsandMethods
2.1. Cell Culture. Human hepatocellular carcinoma cell
line HepG2, human cervical cancer cell line HELA, and2 Biochemistry Research International
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Figure 1: Localization of TCTP in HepG2 cells (a), HL-7702 cells (b) and HeLa cells (c), A1–A3: 12h, ×400; B1–B3: 24h,×400; C1–
C3:48h,×400; D1–D3: 60h, ×400.Biochemistry Research International 3
human normal hepatocyte cell line HL-7702 were purchased
from Chinese Academy of Science (Shanghai) and grown
in Dulbecco’s Modiﬁed Eagle Medium (DMEM)(GIBCO,
Invitrogen, USA) supplemented with 10% FBS (ExCell,
Genetimes, China), maintained at 37◦C, 95% humidity, and
5% carbon dioxide.
2.2. Reagent and Antibodies. The rabbit polyclonal antibody
for TCTP, rabbit polyclonal antibody for TSAP6, and
goat polyclonal secondary antibody to rabbit IgG-H&L
(FITC) were purchased from Abcam. Paraformaldehyde and
Tween20 were purchased from Sigma-Aldrich. The 4,6-
Diamidine-2-phenylindole dihydrochloride (DAPI), Bovine
Serum Albumin (BSA), antifade mounting medium, and
phosphate-buﬀered saline were purchased from Roche,
Solarbio, Beyotime, and Zhongshan Golden Bridge Biotech,
respectively.
2.3. Immunostaining and Microscopy. For indirect immuno-
ﬂuorescence, HepG2, HL-7702, and HeLa cells were cultured
oncoverslipsandﬁxedwith4%paraformaldehydeafter12h,
24h, 48h, and 60h culture, respectively, then permeabilized
with 0.2% Tween20, blocked with 1% BSA for 1h, and
incubated with the rabbit polyclonal to TCTP (1:500) and
TSAP6 (1:200), respectively, overnight at 4◦C, coupled with
the secondary antibody at 4◦Cf o r6h o u r s .D A P Iw a su s e d
to stain the nucleus. Immunoﬂuorescence staining imaging
was captured using Laser Confocal Scanning Microscope
(LCSM).
3. Results
3.1. Localization of TCTP. As shown in Figure 1,T C T P
proteinwasmainlylocalizedinthecytoplasmandmembrane
from 12h to 24h, then in both nucleus and cytoplasm from
48 to 60h in HepG2 cells (Figure 1(a)). In HL-7702 cells, the
localization of TCTP protein showed a “nucleus-cytoplasm-
nucleus”patternatdiﬀerenttimepoints(Figure 1(b)).TCTP
localizedinnucleusandcytoplasminHeLacellsateverytime
point (Figure 1(c)).
4. Discussion and Conclusion
Previous reports from Arcuri’s group [15]h a v ed e m o n -
strated localization of TCTP protein in human prostate
and prostate cancer cells using immunohistochemistry
and immunoﬂuorescence staining. The protein was mainly
expressed in the secretory luminal epithelial and basal layer
cells. A signiﬁcant amount of protein was present in the
prostatic ﬂuids. Subcellular distribution studies on prostate
epithelial cells showed the protein localized in the cytoplasm
in interphase and colocalized with tubulin during mitosis.
Li’s group [14] has demonstrated that the intracellular
localization of TCTP was present predominantly in the
nucleus in HeLa cells after transfection with exogenous
TCTP expression plasmid. Amson et al. and Ohgami et
al. found that TCTP was secreted through an endoplasmic
reticulum/Golgi-independent or nonclassical pathway and
that the secreted TCTP was originated from preexisting
pools. TSAP6, a p53-inducible 5-6 transmembrane protein
[17, 18], was found to interact with TCTP and they partially
colocalized in exosomes, some vesicular-like structures at
the plasma membrane and around the nucleus. Functionally,
the overexpression of TSAP6 consistently leads to enhanced
secretion of both endogenously and exogenously expressed
TCTP [16, 17]. We initiated our work by asking whether
TCTP expression can be translocated and what is the
relationship between its secretion level and function. For
the ﬁrst time, using the approach of immunoﬂuorescence
staining, we found that TCTP localized at diﬀerent part
within cells via several experiments. As demonstrated above,
TCTP protein expression could be translocated along with
cell growth.
Interesting phenomena of our results were that TCTP
localization diﬀered between cell lines at the same time
points and that TCTP did not change its cellular localization
inHeLacells,whichcanbeexplainedasfollows.(1)Diﬀerent
characteristics of cell lines. Firstly, HeLa cell is immortal
because of being infected by the human papilloma virus
(HPV). Unlike HeLa, HepG2 cells and HL-7702 cells have
diﬀerent cell cycles and are easy to die. Secondly, diﬀerent
cell lines have diﬀe r e n tc e l lc y c l e si nw h i c hT C T Pp l a y sa
key role. (2) Diﬀerent TCTP expression levels. TCTP is an
antiapoptotic and conservedprotein. Numerousstudies have
shown that TCTP expression level in tumor is higher than
that in the corresponding normal tissues, and inhibition of
TCTP expression can attenuate malignant phenotypes [7],
indicating TCTP has a critical role in tumorigenesis. There-
fore, translocation of subcellular TCTP at diﬀerent times
might reﬂect its biological functions, and the underlying
mechanism needs further investigation.
In summary, we reported the localization and dynamic
translocation of TCTP in diﬀerent cell lines. TCTP localized
in both cytoplasm and nucleus and it translocated into
diﬀerent subcellular units along with cells growth. Our
ﬁnding provides more evidence showing the association
between TCTP localization and function, improving our
understanding of the important role of TCTP in cancer
formation.
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